Ribavirin inhibits the activity of mtor/eif4e, ERK/Mnk1/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemia

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Shi, Fangfang ^a   Len, Yamei ^a   Gong, Yuping ^a   Shi, Rui ^a   Yang, Xi ^a   Naren, Duolan ^a   Yan, Tianyou ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 1; PROTEIN MCL 1; RIBAVIRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MKNK1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEX FORMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; K562 CELL LINE; LEUKEMIA CELL LINE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PHILADELPHIA 1 CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMATINIB MESYLATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE SIGNALING SYSTEM; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; RIBAVIRIN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84943279569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136746     Document Type: Article

References (32)

1. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarkerwith prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 2011;17(9):2874-84. doi: 10.1158/1078-0432. CCR-10-2334 PMID: 21415224
2. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009;69(9):3866-73. doi: 10.1158/0008-5472. CAN-08-3472 PMID: 19383915
3. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009;114(2):257-60. doi: 10.1182/blood-2009-02-205153 PMID: 19433856
4. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosinemRNAcap. Proc Natl Acad Sci USA 2004;101(52):18105-10. PMID: 15601771
5. Muta D, Makino K, Nakamura H, Yano S, Kudo M, Kuratsu J. Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neurooncol 2011;101(1):33-9. doi: 10.1007/s11060-010-0233-6 PMID: 20499137
6. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010;16(20):4914-20. doi: 10.1158/1078-0432. CCR-10-0433 PMID: 20702611
7. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136(4):731-45. doi: 10.1016/j.cell.2009.01.042 PMID: 19239892
8. Silva RL, Wendel HG. MNK, EIF4E and targeting translation for therapy. Cell Cycle 2008;7(5):553-5. PMID: 18256539
9. Hay N. Mnk earmarks eIF4E for cancer therapy. Proc Natl Acad Sci USA 2010;107(32):13975-6. doi: 10.1073/pnas.1008908107 PMID: 20679238
10. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21(24):3232-7. PMID: 18055695
11. Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia 2011;25(7):1197-200. doi: 10.1038/leu.2011.57 PMID: 21455212
12. Tan K, Culjkovic B, Amri A, Borden KL. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun 2008;375(3):341-5. doi: 10.1016/j.bbrc.2008.07.163 PMID: 18706892
13. Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol 2008;181(1):51-63. doi: 10.1083/jcb.200707018 PMID: 18391071
14. Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, et al. Further evidence that ribavirin interacts with eIF4E. RNA 2005;11(12):1762-6. PMID: 16251386
15. Kökény S, Papp J, Weber G, Vaszkó T, Carmona-Saez P, Oláh E. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res 2009;29(6):1971-80. PMID: 19528454
16. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999;189(9):1399-412. PMID: 10224280
17. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112(13):4808-17. doi: 10.1182/blood-2008-07-077958 PMID: 19064740
18. Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109(4):1408-13. PMID: 17062730
19. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupJ. Clin Oncol 2006;24(3):460-6.
20. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2011;2011:231-7. doi: 10.1182/asheducation-2011.1. 231 PMID: 22160039
21. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011;117(8):1583-94. doi: 10.1002/cncr. 25690 PMID: 21472706
22. Shi F, Yang X, Gong Y, Shi R, Yang X, Naren D, et al. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Anticancer Drugs. 2015 Apr; 26(4):410-21. doi: 10.1097/CAD.0000000000000200 PMID: 25535978
23. Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogen 2007;26(8):1188-200.
24. Zhou YP. The calculation of ID50 in new drugs with software SPSS. Prog Pharm Sci 2003;27(5):314-316.
25. Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012;13(13):1244-54. doi: 10.4161/cbt.21460 PMID: 22895079
26. Meng H, Jin Y, Liu H, You L, Yang C, Yang X, et al. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol 2013;6:18. doi: 10.1186/1756-8722-6-18 PMID: 23415012
27. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114(8):1618-27. doi: 10.1182/blood-2008-10-184515 PMID: 19458359
28. Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 2008;28(20):6496-509. doi: 10.1128/MCB.00477-08 PMID: 18694961
29. Goetz C, Everson RG, Zhang LC, Gromeier M. MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol Ther 2010;18(11):1937-46. doi: 10.1038/mt.2010.145 PMID: 20648000
30. Messina V, Di Sauro A, Pedrotti S, Adesso L, Latina A, Geremia R, et al. Differential contribution of the MTOR and MNK pathways to the regulation of mRNA translation in meiotic and postmeiotic mouse male germ cells. Biol Reprod 2010;83(4):607-15. doi: 10.1095/biolreprod.110.085050 PMID: 20574055
31. Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 2011;71(15):5204-13. doi: 10.1158/0008-5472. CAN-10-4531 PMID: 21670080
32. Zhao Y, Coloff JL, Ferguson EC, Jacobs SR, Cui K, Rathmell JC. Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. J Biol Chem 2008;283(52):36344-53. doi: 10.1074/jbc. M803580200 PMID: 18990690